Vizimpro

Vizimpro (dacomitinib) is an oral prescription medication used for treating certain types of non-small cell lung cancer. This overview covers key details for informational purposes only. Always consult a healthcare provider for personalized advice.

Vizimpro is primarily used for treating non-small cell lung cancer (NSCLC) in patients with specific genetic mutations. It belongs to a class of drugs known as tyrosine kinase inhibitors, which target cancer cells. The medication is designed to slow the progression of cancer in eligible patients. It is not suitable for all types of lung cancer.

Vizimpro works by blocking signals that promote cancer cell growth. Patients may experience improved symptoms related to their condition over time. Common effects include reduced tumor size and slower disease progression. Individual responses to the medication vary widely.

Store Vizimpro at room temperature, away from moisture and heat. Keep the medication in its original packaging until ready to use. Always handle with dry hands to avoid contamination. If a dose is missed, follow the prescribed schedule; do not double up doses.

Vizimpro may interact with other medications, including strong CYP3A4 inhibitors or inducers. Alcohol and certain herbal supplements can also affect its efficacy. Always inform your healthcare provider about all medications and supplements you are taking. Grapefruit products should be avoided.